

ABBOTT ACQUIRES ST. JUDE MEDICAL

STRONG AND DIVERSE MEDICAL DEVICE PORTFOLIO



HEART FAILURE



CARDIAC RHYTHM
MANAGEMENT



ATRIAL FIBRILLATION



STRUCTURAL
HEART DISEASE



CARDIOVASCULAR



NEUROMODULATION



CORONARY
ARTERY DISEASE



MITRAL
REGURGITATION



PERIPHERAL
ARTERY DISEASE

GLOBAL LEADERSHIP POSITIONS IN DEVICES, DIAGNOSTICS, NUTRITIONALS AND MEDICINES

ALIGNED TO TRENDS

More than **40%**

of U.S. adults are
expected to have
cardiovascular
disease by 2030

LEADERSHIP POSITIONS

1 OR **2**

across large and
high-growth
cardiovascular
disease device
markets



**RELIABLE,
SUSTAINABLE
GROWTH**

Powerful Product Pipeline

EnSite Precision™

ConfirmRx™
Implantable Cardiac
Monitor*

HeartMate 3®*

Portico™*

Proclaim™*

Absorb™

MitraClip®



**LEADING GLOBAL
PRESENCE**

Together, the company has
strong positions around the world,
advancing Abbott's global scale,
infrastructure and capabilities.

- Driving new growth
- Providing more innovative solutions
- Addressing more areas of care
- Creating long-term shareholder value
- Helping more people – across more geographies

*Caution: Investigational device.
Limited by federal (or U.S.) law
to investigational use.
Not available for sale in the U.S.



Private Securities Litigation Reform Act Of 1995

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements, including but not limited to the ability of Abbott to successfully integrate St. Jude Medical's operations, and the ability of Abbott to implement its plans, forecasts and other expectations with respect to St. Jude Medical's business and realize expected synergies. Economic, competitive, governmental, technological and other factors

that may affect Abbott's and St. Jude Medical's operations are discussed in Item 1A, "Risk Factors," in each of Abbott's Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2015, and St. Jude Medical's Annual Report on Securities and Exchange Commission Form 10-K for the year ended Jan. 2, 2016, respectively, and under the heading "Risk Factors" in Abbott's Quarterly Report on Form 10-Q for the six months ended June 30, 2016, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.